Skip to content

Tiziana nabs new U.S. patent for TZLS-501 in potential COVID-19 treatment

August 24, 2020

The USPTO has granted Tiziana Life Sciences (NASDAQ:TLSA) a patent for methods and use of fully human monoclonal antibody (mAb; TZLS-501) that recognizes both IL-6 receptor (IL-6R) and IL-6 receptor complex with IL-6 (IL-6R/IL-6) for prophylactic and therapeutic intervention for human diseases.

The Patent No. 10,759,862 will be published on September 1. This additional patent on TZLS-501 is significant for the potential treatment of COVID-19 and acute respiratory distress syndrome (ARDS).

“We are expediting the clinical development of TZLS-501, GMP manufacturing, simultaneously developing inhalation delivery directly to the lungs using a nebulizer and conducting the inhalation safety toxicology studies in Cynomolgus monkeys. Completion of these studies will enable us to file an IND and initiate a clinical trial in COVID-19 patients by Q1 2021,” added Dr. Kunwar Shailubhai, CEO and CSO of Tiziana.

From → Uncategorized

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: